Targeting the CaN/FoxO1/FABP4 Axis in SERCA2 Dysfunction-Driven Atherosclerosis

Study Background and Research Question

Atherosclerosis, a chronic inflammatory disease, is driven by the accumulation of lipid-laden plaques within arterial walls and remains a major cause of myocardial infarction and stroke. Macrophage-derived foam cell formation, resulting from dysregulated lipid uptake and metabolism, is a pivotal event in disease progression. Sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2) maintains cellular calcium homeostasis, and its dysfunction has been implicated in exacerbating atherosclerosis by promoting endoplasmic reticulum stress and inflammation in vascular cells. However, the precise molecular mechanisms linking SERCA2 dysfunction to macrophage foam cell formation and lipid dysregulation have remained unclear (paper).

Key Innovation from the Reference Study

The referenced work by Zhu et al. provides a mechanistic breakthrough by identifying the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) signaling pathway as a critical mediator of SERCA2 dysfunction-induced foam cell formation. The study demonstrates that aberrant SERCA2 activity, specifically the C674S mutation, triggers upregulation of CaN, which in turn activates FoxO1. Activated FoxO1 translocates to the nucleus, driving increased transcription of FABP4. Elevated FABP4 promotes fatty acid uptake and synthesis, ultimately enhancing foam cell formation in macrophages. By demonstrating that inhibition of this pathway, either genetically or pharmacologically, can prevent lipid accumulation and atherogenesis, the authors uncover a potential therapeutic target for atherosclerosis (paper).

Methods and Experimental Design Insights

The study employs a multi-tiered approach:

• Genetic Model: Heterozygous SERCA2 C674S knock-in (SKI) mice were generated to mimic SERCA2 dysfunction in vivo. These mice, along with wild-type controls, provided the basis for comparative atherosclerosis studies.
• Metabolomics: Serum from SKI and wild-type mice was subjected to metabolomic profiling to identify systemic changes in lipid metabolism.
• Histology and Lesion Quantification: The entire aorta and aortic root were isolated for histological analysis, quantifying plaque burden and foam cell content.
• Cellular Assays: Bone marrow-derived macrophages (BMDMs) were isolated for functional assays, including protein expression (immunoblotting), lipid uptake (fluorescent fatty acid analogs), and lipid accumulation (Oil Red O staining).
• Pathway Intervention: Pharmacological inhibitors targeting FoxO1 or FABP4, as well as genetic partial deficiency of FABP4, were employed to dissect pathway contributions.

This rigorous design enabled direct attribution of observed phenotypes to the CaN/FoxO1/FABP4 pathway in the context of SERCA2 dysfunction (paper).

Core Findings and Why They Matter

Key findings include:

• SERCA2 Dysfunction Activates CaN/FoxO1/FABP4: The C674S mutation in SERCA2 significantly upregulated CaN expression, promoted nuclear translocation of FoxO1, and increased FABP4 transcription in BMDMs (paper).
• Aberrant Lipid Metabolism and Foam Cell Formation: SKI BMDMs exhibited heightened fatty acid synthesis and lipid droplet accumulation, leading to increased foam cell formation compared to wild-type controls (paper).
• Pharmacological Inhibition Corrects Phenotype: Inhibitors of FoxO1 or FABP4, as well as partial FABP4 deficiency, normalized lipid metabolism, reduced foam cell formation, and attenuated atherosclerotic lesion development in SKI mice (paper).

These results support a model in which SERCA2 dysfunction drives atherosclerosis by engaging a specific signaling axis that regulates fatty acid handling in macrophages. Importantly, targeting FABP4 emerges as a tractable intervention point, with direct implications for designing new therapeutics for atherosclerosis and related metabolic conditions.

Comparison with Existing Internal Articles

Several recent reviews and workflow articles have discussed the experimental and translational value of FABP4 inhibition in cardiovascular and metabolic disease models:

• The article "Disrupting the CaN/FoxO1/FABP4 Axis Mitigates Atherosclerosis Progression" closely parallels the present study, emphasizing the mechanistic significance of this signaling axis and the benefits of pharmacological FABP4 blockade for correcting lipid metabolic derangements in foam cell formation. Zhu et al.'s work provides direct in vivo genetic and pharmacological validation of this mechanism.
• "BMS 309403: FABP4 Inhibitor Workflows for Atherosclerosis Research" and "BMS 309403: Selective FABP4 Inhibitor for Atherosclerosis Research" focus on practical aspects of deploying BMS 309403 as a potent FABP4 inhibitor in cell-based and animal models, supporting protocol optimization and highlighting its use in dissecting lipid metabolism and inflammation. The current reference paper experimentally reinforces the rationale for targeting FABP4, as outlined in these workflow resources.
• "BMS 309403: Advancing Atherosclerosis and Metabolic Disease Research" elaborates on assay design and translational applications for BMS 309403, dovetailing with the findings that selective FABP4 inhibition mediates protective effects in models of aberrant lipid metabolism.

Taken together, the referenced research provides a molecular and functional foundation for the protocols and applications advocated in the above workflow articles.

Limitations and Transferability

While the study leverages robust in vivo and in vitro models, some limitations are noteworthy:

• Genetic Model Specificity: The SERCA2 C674S knock-in mouse models a specific pathological mutation; extrapolation to other forms of SERCA2 dysfunction or to human populations may require further validation (paper).
• Cellular Focus: The primary mechanistic studies were conducted in bone marrow-derived macrophages. Although endothelial cells were implicated, the dominant evidence centers on macrophage-driven foam cell formation.
• Pharmacological Specificity: While FABP4 inhibition clearly ameliorates atherosclerosis in this context, potential off-target or compensatory metabolic effects, particularly in chronic settings, require long-term study (paper).

Nevertheless, the CaN/FoxO1/FABP4 pathway represents a robust mechanistic node for intervention in SERCA2 dysfunction-driven disease.

Protocol Parameters

• in vitro FABP4 inhibition (macrophage foam cell assay) | 1–25 μM BMS 309403 | THP-1 or primary BMDMs | Dose-dependent reduction in MCP-1 secretion and foam cell formation | product_spec
• in vivo atherosclerosis model (ApoE-/- mice) | chronic administration of BMS 309403 (refer to paper for specific dosing regimens) | Mouse models of atherosclerosis | Improves endothelial function, reduces lesion area, enhances glucose uptake via AMPK activation | product_spec, paper
• storage and solubility | solid at -20°C; soluble in DMSO ≥18.15 mg/mL, ethanol ≥48.4 mg/mL | All in vitro and in vivo experimental workflows | Ensures compound stability and optimal delivery | product_spec
• FABP4 pathway inhibition (genetic or pharmacological) | partial deficiency or use of BMS 309403 | BMDM and animal models | Ameliorates lipid accumulation and atherosclerotic lesion progression | paper

Research Support Resources

For researchers aiming to replicate or extend these workflows, BMS 309403 (SKU B7794) is available as a potent and selective FABP4 inhibitor. APExBIO supplies this compound for use in cell-based and animal studies, with detailed solubility and storage guidelines to support robust experimental design (source: product_spec). The integration of BMS 309403 into protocols targeting lipid metabolism, inflammation, or atherosclerotic lesion formation is supported by both product specifications and recent mechanistic literature (paper).